Table 1.
Outcome and characteristics of the investigated study population of patients with PcP
| Overall 240 (100%) |
HIV 125 (52%) |
SOT 39 (16.3%) |
ChTx 38 (15.8%) |
IS/RD 28 (11.7%) |
MISC 10 (4.2%) |
|
|---|---|---|---|---|---|---|
| Age (years) | 44.8 ± 14.6 | 41 ± 10.6 | 49.5 ± 13.9*** | 49.7 ± 17.2*** | 51.2 ± 17.6*** | 37.3 ± 24.5 |
| Women | 67 (27.9%) | 18 (14.4%) | 11 (28.2%) | 17 (44.7%)♦♦♦ | 15 (53.6%)♦♦♦ | 6 (60%)♦♦ |
| ICU admission | 100 (41.7%) | 31 (24.8%) | 19 (48.7%)♦♦ | 27 (71.1%)♦♦♦ | 16 (57.1%)♦♦ | 7 (70%)♦♦ |
| Mechanical ventilation | 88 (36.7%) | 26 (22.4%) | 17 (43.6%)♦ | 21 (55.3%)♦♦♦ | 16 (57.1%)♦♦♦ | 6 (60%)♦ |
| CRRT | 39 (16.3%) | 4 (3.2%) | 19 (48.7%)♦♦♦ | 6 (15.8%)♦ | 7 (25%)♦♦♦ | 3 (30%)♦♦ |
| ECMO/ECLA treatment | 11 (4.6%) | 5 (4%) | 3 (7.7%) | 2 (5.3%) | 1 (3.6%) | 0 (0%) |
| in-hospital mortality (%) | 61 (25.4%) | 16 (12.8%) | 15 (38.5%)♦♦ | 17 (44.7%)♦♦♦ | 10 (35.7%)♦♦ | 3 (30%) |
| TMP-SMX prophylaxis (%) | 12 (5%) | 6 (4.8%) | 1 (2.6%) | 5 (13.2%) | 0 (0%) | 0 (0%) |
| initial LDH (U/L) | 502.1 ± 281.6 | 482.2 ± 247.2 | 482.5 ± 374.0 | 498.0 ± 236.4 | 627.3 ± 347.2 * | 493.5 ± 160.5 |
Abbreviations: PcP Pneumocystis pneumonia, ICU intensive care unit, CRRT continuous renal replacement therapy, ECMO extracorporeal membrane oxygenation, ECLA extracorporeal lung assist, TMP-SMX trimethoprim-sulfamethoxazole, HIV human immunodeficiency virus, SOT solid organ transplantation, ChTx chemotherapy, IS/RD immunosuppression/rheumatic diseases. MISC miscellaneous
Difference compared to HIV-positive patients (Fisher’s exact test): ♦p < 0.05, ♦♦p < 0.01, ♦♦♦p < 0.001
Difference compared to HIV-positive patients (Mann–Whitney U test): *p < 0.05, **p < 0.01, ***p < 0.001